DC
BBIO icon

Diametric Capital’s BridgeBio Pharma BBIO Stock Holding History

Diametric Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,076
Closed -$306K – 380
2024
Q2 		$306K Buy
+12,076
New +$330K 0.17% 176

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diametric Capital's BBIO Position: Q3 2024 in Review

Diametric Capital sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 12,076 shares — an estimated $306K sold.

Diametric Capital first reported a position in BBIO in Q2 2024 and held it in 1 quarter. The position peaked at $306K in Q2 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • Diametric Capital reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • Diametric Capital sold 12,076 BridgeBio Pharma shares in Q3 2024, an estimated $306K.
  • Diametric Capital first reported a position in BridgeBio Pharma in Q2 2024 and held it in 1 quarter.
  • Diametric Capital's BridgeBio Pharma position peaked at $306K in Q2 2024.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Diametric Capital's 13F filing for Q3 2024, filed 13 Nov 2024.